ERBB2 and cancer: By leveraging RNA sequencing, network pharmacology, molecular docking, and molecular dynamics, this study has elucidated how bioactive metabolites like C3G and ursolic acid interact with key cancer-related proteins, such as PTGS2, HSP90AA1, and ERBB2.